


**Figure 1 – PEPTIDES DERIVED FROM NATURAL CASEIN STIMULATE MURINE NATURAL KILLER (NK) CELL ACTIVITY.**


Group > Ex. No v	1:25		1:50	
	Control	Chay-13	Control	Chay-13
1	16.10	43.80	27.50	62.80
2	25.70	45.40	18.20	43.40
3	0.00	3.10	0.00	35.00
4	-	-	9.00	35.00
Average	13.93	30.77	13.68	44.05
SD	12.99	23.97	11.84	13.11

### CHAY-13 EFFECT ON NK ACTIVITY



**Figure 2a – EFFECT OF PEPTIDES DERIVED FROM NATURAL CASEIN ON HUMAN NATURAL KILLER (NK) CELL ACTIVITY IN CELLS FROM A SINGLE DONOR.**

Dose >	0	5	10	25	50	100	250	500
1:50	3.9	5.4	11.3	10.9	9.1	8.3	12.5	15.5
1:100	4.6	5.1	12.4	12.8	11.9	10.8	12.1	14.9




**Figure 2b SELECTIVE STIMULATION OF HUMAN NATURAL KILLER (NK) CELL ACTIVITY BY PEPTIDES DERIVED FROM NATURAL CASEIN.**

Patient	Type	0	10	25	100	250	500
1	Normal	13	15	15	12	13	15
2	NHL	10.1	13.8	14.3	-	15.8	13.7
3	NHL	3.5	10.4	8.4	10.8	-	-
4	Br. Ca.	4.2	2.7	7.1	7.7	5.9	10.1
5	-	12.2	18.1	19.1	14.3	13.4	15.8
6	-	17	15	15	15	13	9


**Figure 3a – PEPTIDES DERIVED FROM NATURAL CASEIN STIMULATE PROLIFERATION OF HUMAN CD56<sup>+</sup> SURFACE ANTIGEN POSITIVE (NK) CELLS.**

Patient	Control	Chay-13
1	0.60	0.20
2	0.60	1.90
3	0.10	0.90
4	0.40	3.30
5	1.50	3.70
Mean	0.64	2.00
SD	0.52	1.50



**Figure 3b – PEPTIDES DERIVED FROM NATURAL CASEIN STIMULATE PROLIFERATION OF HUMAN CD<sub>3</sub> SURFACE ANTIGEN POSITIVE (T) CELLS.**

Patient	Control	Chay-13
1	7.90	10.40
2	8.19	10.46
3	12.82	58.64
4	62.86	50.44
5	5.49	47.76
Mean	19.45	35.54
SD	24.41	23.27



**Figure 3c – PEPTIDES DERIVED FROM NATURAL CASEIN STIMULATE PROLIFERATION OF HUMAN CD<sub>56</sub> AND CD<sub>3</sub> SURFACE ANTIGEN POSITIVE (NK/T) CELLS.**

Patient	Control	Chay-13
1	8.00	25.00
2	1.1	4.3
3	0.1	0.85
4	2.77	3.89
5	1.74	4.34
6	0.84	4.53
7	0	2.55
Mean	2.08	6.49
SD	2.78	8.27





FIG. 4 - The effect of synthetic peptides on the stimulation of NK cells activity in cultured human PBC.

PEPTIDE	0	10	25	100	250	500
1a	4.3%	4.3%	4.3%	4.3%	4.3%	4.3%
2a	4.3%	4.3%	4.3%	4.3%	4.3%	4.3%
3a	4.3%	4.3%	4.3%	4.3%	4.3%	4.3%


  

PEPTIDE	0	10	25	100	250	500
1a	4.3%	4.3%	4.3%	4.3%	4.3%	4.3%
2a	4.3%	4.3%	4.3%	4.3%	4.3%	4.3%
3a	4.3%	4.3%	4.3%	4.3%	4.3%	4.3%




**FIG. 5a-c – PEPTIDES DERIVED FROM NATURAL CASEIN STIMULATE  
PROLIFERATION OF CULTURED HUMAN PERIPHERAL BLOOD STEM CELLS.**


Blood origin	Incubation period (days)	Control	50 (µg/ml)	100 (µg/ml)	300 (µg/ml)	600 (µg/ml)
PBSC	20	1663	3007	1800	4306	3310
PBSC	15	741	1612	784	-	920
BM normal	21	675	-	660	834	817
BM Auto	21	945	-	916	1537	1284
BM 1	21	1829	4217	4396	9178	1446
BM 2	21	1829	5039	2939	1496	-
CBI	14	1159	1191	1694	3961	3297
CB2	14	3434	-	10882	-	13560



**FIG. 5b**



**FIG. 5a**



**FIG. 5c**

**Figure 6**

**PEPTIDES DERIVED FROM NATURAL CASEIN STIMULATE  
PROLIFERATION OF NORMAL HUMAN HEMATOPOIETIC  
CELLS.**

Donor	Days Of Incubation	Factors Added	Relative Cell No. X 10 <sup>4</sup> /ml				
			<u>0</u>	<u>25</u>	<u>100</u>	<u>250</u>	<u>500</u>
Bone Marrow	14	EPO, hIL-3, hSCF, AB serum	41	64	-	67	51
Cord Blood	13	EPO, hIL-3, hSCF, AB serum	27	158	66	50	-



# Synthetic Casein-Derived Peptides

FIGURE 7

## EFFECT OF PEPTIDE LENGTH ON RELATIVE CELL DISTRIBUTION (DIFFERENTIAL COUNT)


(%)

Identification	PEPTIDE'S LENGTH	CONC. (µg)	Mdp	PMN	EARLY MK	LATE MK	TOTAL MK	EARLY RBC	LATE RBC	TOTAL RBC	PLASMA CELLS	DENDRITIC CELLS	EOS BAS	MITOSES	TOTAL
74	2	25	17.8	2.6	3.5	3.7	7.2	15.8	20.4	36.2	8.3	23.0	2.8	4	544
1P	3	25	11.3	2.9	8.8	5.4	14.2	16.5	38.6	55.1	6.7	7.5	2.3	9	521
2P	4	25	6.1	2.3	7.4	9.1	16.5	19.4	51.8	71.2	-	-	0.6	4	700
3P	5	25	12.9	1.8	16.0	16.9	32.9	18.9	23.4	42.3	2.2	7.4	0.5	2	551
4P	6	25	22.0	3.1	21.6	24.6	46.2	5.7	11.5	17.2	0.1	4.5	4.6	4	842
5P	7	25	30.1	9.0	7.8	7.5	15.3	12.9	12.8	25.7	2.4	14.0	3.5	5	744
X	9	25	30.0	6.6	5.6	3.0	8.6	16.4	18.5	34.9	0.5	15.2	4.3	2	762
2a	11	25	8.6	1.6	14.2	28.9	43.1	13.5	26.5	40.0	3.0	3.0	0.6	12	931
2a	11	250	8.4	0.9	19.4	19.8	39.2	12.6	35.0	47.6	2.2	0.5	1.2	11	651
3a	12	25	9.5	1.8	24.1	22.5	46.6	14.0	23.4	37.4	-	3.7	1.0	16	779
D <sub>1</sub>	16	25	41.0	4.5	7.0	7.6	14.6	9.6	20.2	29.8	3.4	-	6.8	7	471
D <sub>2</sub>	16	250	26.6	4.8	11.9	19.4	31.3	4.2	13.1	17.3	12.3	2.4	4.5	6	620
E <sub>1</sub>	17	100	15.4	5.1	12.9	14.5	27.4	20.5	23.6	44.1	4.5	1.4	2.2	7	552
E <sub>2</sub>	17	1250	7.0	2.1	12.7	19.2	31.9	15.2	36.2	51.4	3.2	0.7	3.8	11	759
F <sub>1</sub>	18	25	17.8	4.6	14.5	19.3	33.8	8.6	24.3	32.9	7.2	-	3.4	9	580
F <sub>2</sub>	18	250	9.9	6.1	18.3	19.5	37.8	15.0	27.9	42.9	2.2	0.5	0.6	13	791
G <sub>1</sub>	19	25	19.9	9.7	14.4	17.0	31.4	8.8	15.3	24.1	9.7	-	5.2	5	659
H <sub>1</sub>	20	25	12.8	3.3	17.0	31.2	48.2	15.4	17.6	33.0	1.8	0.6	0.4	11	826
I <sub>1</sub>	21	25	19.2	9.0	11.9	30.0	41.9	7.9	20.9	28.8	1.4	-	-	8	708
J <sub>1</sub>	22	25	15.0	4.5	13.2	14.0	27.2	18.9	28.4	47.3	4.0	0.2	1.8	15	952
K <sub>1</sub>	23	25	26.6	14.9	3.9	6.5	10.4	3.2	-	3.2	6.5	14.3	22.1	1	154
L	24	25	10.4	3.6	18.9	36.8	55.7	10.3	12.2	22.5	4.6	2.2	0.9	14	768
N	26	100	13.8	3.6	13.6	16.4	30.0	12.4	14.2	26.6	1.5	19.8	4.6	14	675
control (without synthetic peptides)			17.4	1.6	12.4	10.6	23.0	13.1	44.0	57.1	0.3	0.1	0.2	10	686

**Figure 8 – PEPTIDES DERIVED FROM NATURAL CASEIN STIMULATE  
LEUKOCYTE PROLIFERATION IN IRRADIATED, BONE MARROW  
RECONSTITUTED BALB MICE.**

Day After Treatment	2		4		6		9		12		15	
	Control	Chay-13	Control	Chay-13	Control	Chay-13	Control	Chay-13	Control	Chay-13	Control	Chay-13
1	6	9	6	32	55	55	90	205	100	280	500	800
2	10	10	18	34	40	45	135	100	160	280	440	540
3	4	6	14	40	20	85	100	130	140	220	380	800
4	6	6	8	14	35	58	130	125	280	440	600	640
5	12	6	16	18	75	60	70	155	40	340	520	600
6	8	10	18	90	25	45	85	90	320	160	380	640
Mean	7.67	7.83	13.33	38*	41.67	58*	101.67	134.17	173.33	286.67	470	670
SD	2.69	1.86	4.71	24.95	18.63	13.42	23.57	38.01	97.75	88.44	78.95	97.81


\*  $p < 0.008$



**Figure 9 - PEPTIDES DERIVED FROM NATURAL CASEIN STIMULATE THROMBOCYTE PROLIFERATION IN IRRADIATED, BONE MARROW RECONSTITUTED BALB MICE.**

Days After treatment	11		13		15	
	Control	Chay-13	Control	Chay-13	Control	Chay-13
1	43	50	75	103	98	110
2	48	54	71	105	99	128
3	68	68	80	110	102	111
4	64	64	104	104	96	103
5	67	67	91	101	104	133
6	63	54	90	90	97	114
7	54	45	104	107	87	104
8		63		104		116
9		61		93		115
10		57		116		112
Mean	58.14	58.3	87.86	103.3*	97.57	114.6**

\*  $p < 0.01$  \*\*  $p < 0.0001$






Fig. 10

100000x

FIG. 11 –Stimulation of Sup-T<sub>1</sub> Lymphocyte cell proliferation by Peptides Derived from Natural Casein.

Chay13 ? g/ml	3 days		7 days	
	cpm Counts	Proliferation Index	cpm Counts	Proliferation Index
50	9268	1.18	120954	1.10
100	9940	1.26	112436	1.02
300	8425	1.07	102957	0.93
600	9771	1.24	101987	0.93
1000	8390	1.06	86649	0.79
Control	7862		109560	
Chay13 ? g/ml	10 days		14 days	
	cpm Counts	Proliferation Index	cpm Counts	Proliferation Index
50	17695	1.03	22272	1.36
100	19168	1.12	22842	1.40
300	21806	1.28	15318	0.93
600	22826	1.34	17368	1.06
1000	21764	1.28	10034	0.61
Control	17046		16313	

FIG.12 – Peptides Derived from Natural Casein inhibit of HIV-1 infection of CEM cells: Cell proliferation vs. P<sup>24</sup> Antigen levels.

	Chay13 µg/ml	CEM cells	
		Cell No. (x 10 <sup>6</sup> ) 15 days	P <sup>24</sup> Ag Ng/ml
3H	50	0.29	16.39
	100	0.55	7.73
	300	0.54	1.61
	600	0.75	0.18
	1000	0.57	0.19
24H	50	0.40	0.24
	100	0.48	4.21
	300	0.56	2.94
	600	0.62	0.18
	1000	0.79	4.03
48H	50	0.37	10.05
	100	0.50	9.16
	300	0.56	3.21
	600	0.70	16.49
	1000	0.84	2.16
Control	IF	0.35	11.42
	UIF	0.42	0.17

**FIG.13 – Synthetic Casein-Derived Peptides inhibit HIV-1 infection of CEM cells: Cell proliferation vs. P<sup>24</sup> Antigen levels.**

Peptide (3 hr pre-treatment)	Conc. μg/ml	CEM cells	
		Cell No. (x 10 <sup>6</sup> ) 15 days	P <sup>24</sup> Ag ng/ml
<b>1P</b> (SEQ ID NO 3)	<b>100</b>	1.29	0.17
	<b>500</b>	2.01	0.14
<b>3P</b> (SEQ ID NO 5)	<b>10</b>	1.17	0.26
	<b>25</b>	1.26	0.18
<b>4P</b> (SEQ ID NO 6)	<b>25</b>	1.26	0.42
	<b>100</b>	1.00	1.4
	<b>250</b>	1.59	0.10
Control	<b>IF</b>	1.06	0.52
	<b>UIF</b>	0.42	0.17

**Fig. 14: Peptides Derived from Natural Casein Prevent Onset of Type I Diabetes in Non-Obese Diabetic mice.**






FIG. \_15\_ - Total Cholesterol (TC), LDL & HDL levels in Hypercholesterolemic/Hyperlipidemic C57 black mice 1

Sample*	Group**	Food	TC	HDL		LDL
1	Normal	Normal	91	44	48	<1
2		Normal	92	51	56	<1
3	Control	Enriched	375	53	58	305
4		Enriched	411	46	51	348
5	B	Enriched	442	47	52	372
6		Enriched	445	38	42	386
7	C	Enriched	409	47	52	341
8		Enriched	411	34	37	361
9	2a	Enriched	279	33	36	229
10		Enriched	278	43	47	213
11	3P	Enriched	312	38	42	251
12		Enriched	305	39	43	243

\* One blood sample represents blood drawn from 2 mice

\*\* Each group included 4 mice.

#### MEAN VALUES

		TC	HDL	LDL
1+2	Normal	91.5	49.75	<1
3+4	Control	393	52	326.5
5+6	B	443.5	44.75	379
7+8	C	410	42.5	351
9+10	2a	278.5	40	221
11+12	3P	308.5	40.5	247

4

#### Cholesterol, HDL & LDL in C57 Black Mice Treated with Peptides





FIG. 16 - Effect of peptides derived from natural casein on cancer patients hematopoiesis.

Patient	WBC		PLT		RBC		HGB	
	Before	After	Before	After	Before	After	Before	After
1	1,200 n	4,100 241	17,000 n	224,000 1217	3.27 n	4.05 23	10.4 n	12.6 21
2	5,400 n	6,300 16.6	204,000 n	259,000 26.9	3.37 n	3.46 2.6	10.8 n	11.0 1.8
3	3,400 n	5,100 50	12,700 n	17,900 40	4.49 n	4.71 8.4	12.9 n	13.2 2.3
4	700 n	4,600 557	47,000 n	151,000 221	2.88 n	3.45 19.7	8.6 n	10.5 22
5	4,900 n	6,400 30						

WBC - White blood cells  
 PLT - Platelets  
 RBC - Red blood cells  
 HGB - Hemoglobin

Figure 17: Peptides Derived from Native Casein Stimulate Thrombocytopoiesis in Acute Myeloid Leukemia (Patient M-1).

X	Y
0	11
1	10
3	10
5	32.5
7	15
8	27.5
12	40
14.25	28
17	35
21	45
26.35	70.3
31.7	74
40	100.7



**Figure 18: Peptides Derived From Native Casein Stimulate Thrombocytopoiesis in Acute Myeloid Leukemia (Patient M-2).**

X	Y
0	23
1	18.5
2	25
3	16
4	20.8
6	20.8
7	20
8	23.5
9	26
10	19.5
11	23
13	18.5
14	18.5
15	20
17.2	22
20.3	30
24	44
29	75.6
36.5	86.4
41	139.5

